Hormonal
In human obesity, elevated circulating leptin levels do not result in weight loss or reduced adiposity due to central leptin resistance, primarily caused by impaired transport across the blood-brain barrier and downstream signaling defects.
Having high leptin levels does not mean your body is successfully managing your weight. In obesity, the brain stops listening to leptin signals due to transport and signaling issues. This is not a permanent genetic sentence but a reversible physiological state. Weight loss can improve leptin sensitivity, breaking the cycle of resistance.
most subjects with obesity are not deficient in leptin, rather exhibit higher circulating leptin levels than those in non-obese subjects, which is a feature of leptin resistance [10].
Why this rating
The paper is a comprehensive review citing multiple human and animal studies, though specific clinical trial data for general obesity treatment is limited.
Source
Leptin as a key regulator of the adipose organ
Catalina Picó et al. · Reviews in Endocrine and Metabolic Disorders · 2021
DOI 10.1007/s11154-021-09687-5
More from this paper
- Exogenous leptin therapy is effective in treating obesity and metabolic disorders only in individuals with congenital leptin deficiency or generalized lipodystrophy, but is ineffective for the majority of people with common obesity.Strong
- Leptin directly stimulates lipid oxidation and lipolysis in white adipose tissue (WAT) through sympathetic nervous system activation and direct receptor binding, independent of its central effects on food intake.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →